Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Mallika Singh(Revolution Medicines (United States)), David Wildes(Revolution Medicines (United States)), Nicole Nasholm(Revolution Medicines (United States)), Abby Marquez(Revolution Medicines (United States)), Chiara Ambrogio(Dana-Farber Cancer Institute), Lo Lai(Georgia State University), Yu Chi Yang(Revolution Medicines (United States)), Matthew Holderfield(Revolution Medicines (United States)), Adrian L. Gill(AstraZeneca (Sweden)), Jacqueline A.M. Smith(Revolution Medicines (United States)), James Evans(Temple College), Grace Goodhart(University of Cincinnati), Julien Dilly(Massachusetts Institute of Technology), Andrew P. Waters(University of Glasgow), Kyle J. Seamon(Revolution Medicines (United States)), Elena S. Koltun(Revolution Medicines (United States)), John E. Knox(Revolution Medicines (United States)), Nuntana Dinglasan(Revolution Medicines (United States)), Anthony Salvador(Revolution Medicines (United States)), Jennifer A. Roth(Broad Institute), Aidan C.A. Tomlinson(Revolution Medicines (United States)), Piro Lito(Memorial Sloan Kettering Cancer Center), Feng Hu(Memorial Sloan Kettering Cancer Center), David Santamarı́a(Centro de Investigación del Cáncer), Channing J. Der(University of North Carolina at Chapel Hill), Matthew G. Rees(Broad Institute), Stephanie Chang, Lingyan Jiang(Hainan University), Antonio Cuevas-Navarro(Memorial Sloan Kettering Cancer Center), Jim Cregg(Revolution Medicines (United States)), Andrew J. Aguirre(Broad Institute), Ying Wang(Syngenta (China)), Yevgeniy Gindin(Revolution Medicines (United States)), Ethan Ahler(Revolution Medicines (United States)), Alessia Mira(University of Turin), Bianca J. Lee(Revolution Medicines (United States)), Nilufar Montazer(Revolution Medicines (United States)), Enricho Patrucco, Tamar Bar Ziv(Revolution Medicines (United States)), Yang Liu(Mudanjiang Medical University), Anqi Chen(Macau University of Science and Technology), Jingjing Jiang(Revolution Medicines (United States)), Zhengping Wang(Shandong University), Dylan Parsons(Revolution Medicines (United States)), Oliver Lai(Revolution Medicines (United States)), Melissa M. Ronan(Broad Institute), Shurui Cai(The Ohio State University), Anthony N. Milin(Revolution Medicines (United States))
Cited by 5
Related Papers
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k
Activated Kras and <i>Ink4a/Arf</i> deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
|Genes & Development|2003|1k
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
|Nature Cancer|2020|880
Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting
|Cancer Discovery|2016|632